UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Diagnosis and Management of Primary Bone Tumors: Volume 2

Bahk, Won-Jong

1, 2023

Volltextzugriff (PDF)

MM-559 Update on Predictors of Progression in Smoldering Multiple Myeloma: A Systematic Review

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S571-S572

2024

Volltextzugriff (PDF)

MM-161 Talquetamab + Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated TRIMM-2 Results

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S476-S477

2023

Volltextzugriff (PDF)

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments

Frontiers in oncology, 2021-02, Vol.10, p.624661-624661

2021

Volltextzugriff (PDF)

Smouldering multiple myeloma: To seek or not to seek? To treat or not to treat. That is the question

British journal of haematology, 2024-04, Vol.204 (4), p.1141-1142

2024

Volltextzugriff (PDF)

EARLY RELAPSE WITHIN 18 MONTHS (ER18) IS A POWERFUL DYNAMIC PREDICTOR FOR PROGNOSIS AND COULD REVISE STATIC RISK DISTRIBUTION IN PATIENTS WITH NEWLY‐DIAGNOSED MULTIPLE MYELOMA

Hematological oncology, 2023-06, Vol.41 (S2), p.778-779

2023

Volltextzugriff (PDF)

Oral manifestations of multiple myeloma – A systematic review

Oral oncology reports, 2024-06, Vol.10, p.100485, Article 100485

2024

Volltextzugriff (PDF)

MM-162 Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S477-S477

2023

Volltextzugriff (PDF)

MM-509 A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single-Agent Belantamab Mafodotin (Belamaf) Compared With Pomalidomide Plus Low-Dose Dexamethasone (Pd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) (DREAMM-3)

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S504-S505

2023

Volltextzugriff (PDF)

MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S478-S479

2023

Volltextzugriff (PDF)

MM-246 Isatuximab (Isa) in Relapsed Multiple Myeloma (MM) Patients (pts) With Ultra-High-Risk (UHR) Cytogenetics: ICARIA-MM and IKEMA Subgroup Analysis

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S484-S484

2023

Volltextzugriff (PDF)

MM-192 Preliminary Recommendations for Prevention and Management of Infections, Hypogammaglobulinemia, and Neutropenia During Treatment With Teclistamab Based on Experience From the MajesTEC-1 Study

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S480-S481

2023

Volltextzugriff (PDF)

MM-191 Analysis of Infections and Parameters of Humoral Immunity in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Talquetamab (tal) Monotherapy in MonumenTAL-1

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S480-S480

2023

Volltextzugriff (PDF)

MM-510 Patient-Reported Outcomes in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Low-Dose Dexamethasone (Pd) in the DREAMM-3 Study

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S505-S505

2023

Volltextzugriff (PDF)

MM-163 Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) × CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S477-S478

2023

Volltextzugriff (PDF)

Whole‐body magnetic resonance imaging plus serological follow‐up for early identification of progression in smouldering myeloma patients to prevent development of end‐organ damage

British journal of haematology, 2022-10, Vol.199 (1), p.65-75

2022

Volltextzugriff (PDF)

Autologous hematopoietic stem cell transplantation for multiple myeloma in the age of CAR T cell therapy

Frontiers in oncology, 2024-03, Vol.14, p.1373548-1373548

2024

Volltextzugriff (PDF)

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

British journal of haematology, 2019-08, Vol.186 (4), p.549-560

2019

Volltextzugriff (PDF)

Optimization of treatment of patients with plasma cell myeloma with high cytogenetic risk in Poland

Hematologia (Gdańsk), 2022-10

2022

Volltextzugriff (PDF)

Addition of Elotuzumab to Backbone Treatment Regimens for Multiple Myeloma: An Updated Meta-Analysis of Randomized Clinical Trials

Clinical lymphoma, myeloma and leukemia, 2024-09

2024

Volltextzugriff (PDF)

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

Nature Medicine, 2024-08, Vol.30 (8), p.2235-2241

2024

Volltextzugriff (PDF)

Molecular Pathogenesis of Multiple Myeloma

Hematology/oncology clinics of North America, 2024-04, Vol.38 (2), p.267-279

2024

Volltextzugriff (PDF)

LncRNA HOXB‐AS1 promotes cell growth in multiple myeloma via FUT4 mRNA stability by ELAVL1

Journal of cellular biochemistry, 2020-10, Vol.121 (10), p.4043-4051

2020

Volltextzugriff (PDF)

Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma

Expert opinion on biological therapy, 2024-05, Vol.24 (5), p.1-350

2024

Volltextzugriff (PDF)

Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival

European journal of haematology, 2018-08, Vol.101 (2), p.237-244

2018

Volltextzugriff (PDF)

1 – 25 von 23.052

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(12.739)
Mit Volltextzugriff
(14.438)

Publikationsform

7 weitere anzeigen...

Weniger anzeigen...

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Multiple Myeloma
(22.601)
Science & Technology
(8.972)
Life Sciences & Biomedicine
(8.595)
Oncology
(5.231)
Patients
(4.317)
Hematology
(3.998)
Cancer
(3.292)
Bone Marrow
(3.054)
Lymphoma
(2.328)
Clinical Trials
(2.291)
Chemotherapy
(2.266)
Cancer Therapies
(2.251)
Proteins
(2.212)
Leukemia
(2.186)
Tumors
(2.083)
Care And Treatment
(1.779)
Immunotherapy
(1.694)
Medical Prognosis
(1.571)
Medical Research
(1.544)
Pharmaceutical Industry
(1.519)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Reactions Weekly
(1.245)
Pr Newswire
(943)
Business Wire
(789)
Cancers
(605)
Clinical Lymphoma, Myeloma And Leukemia
(355)
Curēus
(305)
M2 Presswire
(276)
Frontiers In Oncology
(272)
British Journal Of Haematology
(202)
Oncology Letters
(181)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Diagnosis and Management of Primary Bone Tumors: Volume 2

MM-559 Update on Predictors of Progression in Smoldering Multiple Myeloma: A Systematic Review

MM-161 Talquetamab + Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated TRIMM-2 Results

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments

Smouldering multiple myeloma: To seek or not to seek? To treat or not to treat. That is the question

EARLY RELAPSE WITHIN 18 MONTHS (ER18) IS A POWERFUL DYNAMIC PREDICTOR FOR PROGNOSIS AND COULD REVISE STATIC RISK DISTRIBUTION IN PATIENTS WITH NEWLY‐DIAGNOSED MULTIPLE MYELOMA

Oral manifestations of multiple myeloma – A systematic review

MM-162 Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study

MM-509 A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single-Agent Belantamab Mafodotin (Belamaf) Compared With Pomalidomide Plus Low-Dose Dexamethasone (Pd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) (DREAMM-3)

MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

MM-246 Isatuximab (Isa) in Relapsed Multiple Myeloma (MM) Patients (pts) With Ultra-High-Risk (UHR) Cytogenetics: ICARIA-MM and IKEMA Subgroup Analysis

MM-192 Preliminary Recommendations for Prevention and Management of Infections, Hypogammaglobulinemia, and Neutropenia During Treatment With Teclistamab Based on Experience From the MajesTEC-1 Study

MM-191 Analysis of Infections and Parameters of Humoral Immunity in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Talquetamab (tal) Monotherapy in MonumenTAL-1

MM-510 Patient-Reported Outcomes in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Low-Dose Dexamethasone (Pd) in the DREAMM-3 Study

MM-163 Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) × CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Whole‐body magnetic resonance imaging plus serological follow‐up for early identification of progression in smouldering myeloma patients to prevent development of end‐organ damage

Autologous hematopoietic stem cell transplantation for multiple myeloma in the age of CAR T cell therapy

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

Optimization of treatment of patients with plasma cell myeloma with high cytogenetic risk in Poland

Addition of Elotuzumab to Backbone Treatment Regimens for Multiple Myeloma: An Updated Meta-Analysis of Randomized Clinical Trials

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

Molecular Pathogenesis of Multiple Myeloma

LncRNA HOXB‐AS1 promotes cell growth in multiple myeloma via FUT4 mRNA stability by ELAVL1

Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma

Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival

Aktive Filter

Suchergebnisse filtern